CBAY(Delisted)
Cymabay TherapeuticsยทNASDAQ
--
--(--)
CBAY Profile
Cymabay Therapeutics, Inc.
A clinical-stage biopharmaceutical company that developing therapies for liver and other chronic diseases
7575 Gateway Blvd, Suite 110, Newark, CA 94560
--
Cymabay Therapeutics, Inc., was incorporated on October 5, 1988 under the laws of the State of Delaware. CymaBay Therapeutics focuses on the development of therapies for the treatment of metabolism and rare diseases with high demand. Its lead product candidate, Arhalofenate, is currently being developed for the treatment of gout. Arhalofenate has successfully completed Phase 3 clinical trials in gout patients and patients who consistently demonstrate the ability to reduce gout attacks and lower serum uric acid.
